Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 3
2006 3
2007 6
2008 4
2009 3
2010 5
2011 3
2012 2
2013 4
2014 5
2015 3
2016 2
2017 6
2018 4
2019 5
2020 1
2021 7
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease.
Ershler WB, De Castro LM, Pakbaz Z, Moynahan A, Weycker D, Delea TE, Agodoa I, Cong Z. Ershler WB, et al. Among authors: delea te. Curr Ther Res Clin Exp. 2023 Feb 23;98:100696. doi: 10.1016/j.curtheres.2023.100696. eCollection 2023. Curr Ther Res Clin Exp. 2023. PMID: 36950457 Free PMC article.
Lifetime Costs for Treated Follicular Lymphoma Patients in the US.
Eichten C, Ma Q, Delea TE, Hagiwara M, Ramos R, Iorga ŞR, Zhang J, Maziarz RT. Eichten C, et al. Among authors: delea te. Pharmacoeconomics. 2021 Oct;39(10):1163-1183. doi: 10.1007/s40273-021-01052-3. Epub 2021 Jul 17. Pharmacoeconomics. 2021. PMID: 34273085
The Authors Respond.
Delea TE, Amdahl J, Diaz J, Nakhaipour HR, El Khoury MH. Delea TE, et al. J Manag Care Spec Pharm. 2015 Sep;21(9):836-40. J Manag Care Spec Pharm. 2015. PMID: 26536676 No abstract available.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching PA. Jerusalem G, et al. Among authors: delea te. Clin Breast Cancer. 2022 Jun;22(4):326-335. doi: 10.1016/j.clbc.2021.12.008. Epub 2021 Dec 20. Clin Breast Cancer. 2022. PMID: 35034858 Clinical Trial.
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE. Stellato D, et al. Among authors: delea te. Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9. Pharmacoeconomics. 2021. PMID: 34105083
64 results